 |
| Smallpox Treatment Market |
Smallpox is a highly contagious and potentially lethal infectious disease caused by the variola virus. Although globally eradicated, the virus is maintained in laboratory settings for research purposes & may place communities exposed to accidental or deliberate release at risk. Smallpox treatments can prevent, treat and contain outbreaks by protecting high-risk groups and providing post-exposure prophylaxis. The global smallpox treatment market comprises drugs and vaccines used to counter smallpox infection. The global smallpox treatment market is estimated to be valued at US$ 68.7 Mn in 2023 and is expected to exhibit a CAGR of 1.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising risk of biological threats has accelerated the demand for smallpox
treatments over the past decade. State actors and terrorist organizations see
bioweapons as means to undermine nations without conventional military
strength. Hence governments worldwide are stockpiling smallpox countermeasures
as a safeguard against deliberate outbreaks through infected individuals or
environmental releases. Major players are collaborating with national stockpile
programs and expanding manufacturing capacities to fulfill emergency
procurement tenders. New drugs and vaccines in preclinical/clinical phases also
aim to address route of exposure and patient groups not covered by existing
solutions. Such efforts are expected to boost the smallpox treatment market
during the forecast period.
Segment Analysis
The global smallpox treatment market is dominated by antiviral drugs
sub-segment. This is because antiviral drugs were the first line of defense
approved by regulatory authorities for the treatment of smallpox. Tecovirimat
is the only drug approved by FDA for treatment of smallpox. However, vaccines also
have significant share as they help prevent the spread of the infection by
building immunity. Research related to development of newer vaccines and drugs
is ongoing which can drive future growth.
Key Takeaways
The global Smallpox
Treatment Market Growth is expected to witness high growth over the
forecast period. This is attributed to factors such as increasing government
funding for development of medical countermeasures, growing biodefense
spending, approval of Tecovirimat by FDA.
Regional analysis
North America holds the major share of smallpox treatment market and is
expected to maintain its dominance during the forecast period. This is owing to
large biodefense budget of countries like United States, increasing government
initiatives for procurement of vaccines and antiviral drugs to strengthen
preparedness against bioterrorism threats. Europe is the second fastest growing
region due to increasing research activities for development of advanced
treatment options.
Key players
Key players operating in the smallpox treatment market are SIGA Technologies
Inc., Bavarian Nordic A/S, Takeda Pharmaceutical Company Limited, Johnson &
Johnson, Emergent BioSolutions Inc., Novartis International AG, GlaxoSmithKline
plc, Sanofi Pasteur SA, Merck & Co. Inc., Pfizer Inc., Bharat Biotech
International Ltd., BioCryst Pharmaceuticals Inc., Chimerix Inc.,
Nanotherapeutics Inc.
0 Comments